Harmony Biosciences preannounces record Q2 revenue of ~$261M, CFO steps down

Harmony Biosciences Holdings, Inc.

Preliminary Q2 2026 WAKIX net revenue ~$261M, record quarter, up 30% YoY and 21% QoQ.
Reaffirms full-year 2026 net revenue guidance of $1.0B-$1.04B.
CFO Glenn Reicin steps down effective July 16, 2026 to pursue other opportunities.
Stephen Mollichella, SVP and Controller, appointed Interim Principal Financial Officer.
Full Q2 results to be reported on August 4, 2026.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Glenn Reicin

Chief Financial Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2026-07-16
Successor: Stephen Mollichella
Filed: July 16, 2026, 8:35 AM ET

On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.

Appointed (interim)

Stephen Mollichella

Interim Principal Financial Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2026-07-16
Filed: July 16, 2026, 8:35 AM ET

On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn Reicin departed as Chief Financial Officer at Harmony Biosciences Holdings, Inc..

Action: stepping down
Role: Chief Financial Officer

Exact text from the filing

On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Mollichella was appointed as Interim Principal Financial Officer at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Interim Principal Financial Officer

Exact text from the filing

On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-084095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.